Daniel Ness

Prothena (United States) — United States

Medicine · Health Sciences

18h-index2.5kcitations39works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(10), Parkinson's Disease Mechanisms and Treatments(8), Computational Drug Discovery Methods(5), Drug Transport and Resistance Mechanisms(5), Carcinogens and Genotoxicity Assessment(4)

Publications39 total

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
Frontiers in Neurology·2021· 79 citedOpen Access
A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): rationale, design and baseline data
2021· 8 citedOpen Access
The Combination of Tafasitamab and Rituximab Increases Cytotoxicity Against Lymphoma Cells <i>I</i> <i>n Vitro</i>
Blood·2020
Preliminary validation of a novel, comprehensive digital biomarker smartphone application to assess motor symptoms in recently diagnosed Parkinson patients (P4.7-005)
Neurology·2019· 4 cited
UTI in kidney transplant
World Journal of Urology·2019· 27 cited
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease
JAMA Neurology·2018· 283 citedOpen Access
The Role of Clinical Examination in Predicting Relevant MRI Findings in Acute Knee Injuries: A Retrospective Study
The Journal of Knee Surgery·2018· 1 citedOpen Access
Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson’s disease
Parkinsonism & Related Disorders·2018· 4 cited
First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers
Movement Disorders·2016· 242 citedOpen Access
OP0205 Clinical and Preclinical Assessment of The Anti-MCAM Monoclonal Antibody PRX003, A Potential Novel Treatment for Th17-Mediated Inflammatory Diseases
Annals of the Rheumatic Diseases·2016
Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
PLoS ONE·2013· 90 citedOpen Access
Discovery of (<i>R</i>)-4-Cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]quinoline (ELND006) and (<i>R</i>)-4-Cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2<i>H</i>-pyrazolo[4,3-<i>c</i>]quinoline (ELND007): Metabolically Stable γ-Secretase Inhibitors that Selectively Inhibit the Production of Amyloid-β over Notch
Journal of Medicinal Chemistry·2013· 32 cited
Pharmacological inhibition of Polo Like Kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei
Toxicology and Applied Pharmacology·2013· 11 cited
Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors
Bioorganic & Medicinal Chemistry Letters·2012· 11 citedOpen Access
The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo
Blood·2012· 35 cited
Evaluation of combination therapies with MOR00208, an Fc-enhanced humanized CD19 antibody, in models of lymphoma.
Journal of Clinical Oncology·2012· 3 cited
P4‐022: Neuropathology associated with administration of a nonselective beta secretase (BACE) and cathepsin D inhibitor in Mdr 1a/b knockout mice
Alzheimer s & Dementia·2011· 1 cited
P2‐021: Variable effects of the gamma‐secretase inhibitor ELND006 on Aβ across different compartments (brain, ISF, CSF, and plasma) following sustained exposure via subcutaneous osmotic pumps in wild‐type mice
Alzheimer s & Dementia·2011
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease
Alzheimer s Research & Therapy·2010· 50 citedOpen Access
P3‐320: Pharmacokinetic and pharmacodynamic investigation of ELND006, a novel APP‐selective gamma‐secretase inhibitor, on amyloid‐β concentrations in the brain, CSF and plasma of multiple nonclinical species following oral administration
Alzheimer s & Dementia·2010· 12 cited
page 1 of 2Next →

Frequent Co-authors

Elizabeth Brigham(11), Erich Goldbach(11), Gene G. Kinney(8), Guriqbal S. Basi(6), Ruth Motter(6), Wagner Zago(5), Susanne Ostrowitzki(5), Frank Boess(5), Kang Hu(5), Dora Kholodenko(5), Gary D. Probst(5), John‐Michael Sauer(5), Grace Kwong(5), Pamela Santiago(5), Patrick C. May(4), Martin Koller(4), Sue G. Griffith(4), Anna Liao(4), Danielle L. Aubele(4), Michael P. Bova(4)